The Asociación Española Contra el Cáncer (AECC) presents a prize for a study that reveals the capacity of the CPEB4 protein to prevent fatty liver disease.
The research was led by Raúl Méndez from IRB Barcelona and Mercedes Fernández from IDIBAPS.
El Plural has published an article on the project being undertaken by Gonzalo Fernández-Miranda, an associate researcher at IRB Barcelona. The project seeks to develop a better treatment for cancer of the head and neck by means of an immunotherapeutic approach, which has been validated with proof of concept tests at the genetic level.
Link to El Plural
The only one of its kind in Spain, the Master offers practical training in experimental research in various disciplines at centers of excellence including IRB Barcelona.
IRB Barcelona PhD student Marcos Fernández is one of three researchers featured in the article published today in El Mundo, following Friday's ceremony in Madrid, where 68 young scientists received their "la Caixa" doctoral fellowships.
Since the end of 2016, this 25-year old Madrid native has been working towards his PhD degree in the Translational Control of Cell Cycle and Differentiation lab led by ICREA researcher Raúl Méndez. Marcos is studying protein synthesis in several types of tumours.
"I was considering going abroad, but this fellowship was a good incentive to stay," affirms Marcos in the article.
Read the article:...
Gonzalo Fernández-Miranda, associate researcher at IRB Barcelona, leads this therapeutic project selected by CaixaImpulse to facilitate its development towards the market.
Published in the journal Nature Structural & Molecular Biology, the study reveals new insights into translation regulation, an essential step in genome regulation.
These findings will help researchers to better understand pathological processes such as cancer.
"Saber Vivir" magazine dedicates an article to a study—co-led by Cristina Fillat, head of the Gene Therapy and Cancer Group at IDIBAPS, and Raúl Méndez, ICREA researcher at IRB Barcelona—on an innovative approach to provide an adenovirus with high specificity against tumour cells.
The article includes Raúl Méndez's comments about the effectiveness of this new strategy to achieve genetically modified viruses that infect only tumor cells, thus preserving healthy tissues: "It would be effective in a large number of tumours".
La Sexta newscast team has covered the research performed by IDIBAPS Biomedical Research Institute and IRB Barcelona scientists on a new strategy to achieve genetically modified viruses that selectively attack tumor cells without affecting healthy tissues.
"As it is based on mechanisms that do not exist at all in healthy tissue, the oncoselectivity in the animal models we have used is complete", explains ICREA researcher Raúl Méndez, head of the Translational Control of Cell Cycle and Differentiation Lab at IRB Barcelona, talking about his study in...
An innovative programme from IRB Barcelona’s Innovation Department enables researchers to explore how to implement their entrepreneurial ideas
A leading source of news, views and analysis on information about science and technology for global development, SciDev.Net, reports on the research performed by IDIBAPS and IRB Barcelona scientists.
In the study, co-led by Raúl Méndez, ICREA researcher at IRB Barcelona, and Cristina Fillat, head of the Gene Therapy and Cancer Group at IDIBAPS, researchers have designed a new strategy to achieve genetically modified viruses that selectively attack tumor cells without affecting healthy tissues.
“What makes our approach different is the mechanism by which the virus acquires oncoselectivity,” Cristina Fillat explains to SciDev.Net.
Link to ...